Markey Cancer Center's (MCC) Cancer Prevention and Control (CP) Research Program unites highly complementary strengths in the areas of population-based research and community-based cancer control research with the overarching goal of reducing cancer disparities in Kentucky with an emphasis on the state's Appalachian and rural populations. Kentucky has the highest overall cancer incidence and mortality rates among all 50 United States. Alarmingly, the cancer incidence and mortality rates in Appalachian Kentucky are far higher than the rates for the non-Appalachian area of the state. These elevated rates are driven by a variety of underlying factors including low socioeconomic status, low educational attainment, high risk behaviors, cultural barriers, and environmental exposures. Strengths of the CP program include studies focused on uncovering the role environmental exposures play in Kentucky's high cancer incidence rates, testing intervention programs that address unique cultural barriers, and smoking cessation policy development initiatives. CP program members are also national leaders in developing population-based methods and measures that facilitate inter-programmatic cancer research. The CP program combines these strengths to address 3 thematic areas: identification of social, cultural, behavioral, genetic and environmental factors that contribute to the elevated cancer incidence and mortality rates (Theme 1); design, testing, implementation and evaluation of intervention strategies that address identified risk factors (barriers) and reduce the cancer burden (Theme 2); and development of population-based methods and measures that facilitate inter-programmatic cancer research directed at more precisely identifying the distribution of treatment patterns and biomarkers in the population (Theme 3). Most recently, the CP program recruited 2 National Cancer Institute-funded cancer molecular epidemiologists to build on its unique research resources. The current 28-member CP team draws from 5 colleges and 12 departments at the University of Kentucky, thus promoting active interdisciplinary translational research. CP productivity is reflected by total annual external cancer-related funding of over $9.7M ($6.7M annual direct costs) and 245 total publications in the current funding period, 30 (12%) of which are inter-programmatic, 83 (34%) intra-programmatic and 162 (66%) inter-institutional. CP research encompasses all segments of the cancer control continuum: prevention, early detection, treatment and survivorship. CP studies address a number of cancer sites including those that disproportionately contribute to Kentucky's high cancer burden (i.e. lung, colon, breast and cervical cancers). Thus, the CP program is integral to achieving the overall MCC mission to reduce cancer morbidity and mortality in the Commonwealth.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA177558-06S4
Application #
9758765
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Roberson, Sonya
Project Start
Project End
Budget Start
2018-07-01
Budget End
2019-06-30
Support Year
6
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Kentucky
Department
Type
DUNS #
939017877
City
Lexington
State
KY
Country
United States
Zip Code
40526
Liu, Jinpeng; Murali, Thilakam; Yu, Tianxin et al. (2018) Characterization of Squamous Cell Lung Cancers from Appalachian Kentucky. Cancer Epidemiol Biomarkers Prev :
Ore, Robert M; Chen, Quan; DeSimone, Christopher P et al. (2018) Population-Based Analysis of Patient Age and Other Disparities in the Treatment of Ovarian Cancer in Central Appalachia and Kentucky. South Med J 111:333-341
Hubbard, W Brad; Harwood, Christopher L; Geisler, John G et al. (2018) Mitochondrial uncoupling prodrug improves tissue sparing, cognitive outcome, and mitochondrial bioenergetics after traumatic brain injury in male mice. J Neurosci Res 96:1677-1688
Alghamedy, Fatemah; Bopaiah, Jeevith; Jones, Derek et al. (2018) Incorporating Protein Dynamics Through Ensemble Docking in Machine Learning Models to Predict Drug Binding. AMIA Jt Summits Transl Sci Proc 2017:26-34
Wen, Yang-An; Xiong, Xiaopeng; Zaytseva, Yekaterina Y et al. (2018) Downregulation of SREBP inhibits tumor growth and initiation by altering cellular metabolism in colon cancer. Cell Death Dis 9:265
Zhang, Hui; Fredericks, Tricia; Xiong, Gaofeng et al. (2018) Membrane associated collagen XIII promotes cancer metastasis and enhances anoikis resistance. Breast Cancer Res 20:116
Zhong, Weixiong; Weiss, Heidi L; Jayswal, Rani D et al. (2018) Extracellular redox state shift: A novel approach to target prostate cancer invasion. Free Radic Biol Med 117:99-109
Liu, Xinan; Yu, Ye; Liu, Jinpeng et al. (2018) A novel data structure to support ultra-fast taxonomic classification of metagenomic sequences with k-mer signatures. Bioinformatics 34:171-178
Xiong, Gaofeng; Stewart, Rachel L; Chen, Jie et al. (2018) Collagen prolyl 4-hydroxylase 1 is essential for HIF-1? stabilization and TNBC chemoresistance. Nat Commun 9:4456
Jarrett, Stuart G; Carter, Katharine M; Bautista, Robert-Marlo et al. (2018) Sirtuin 1-mediated deacetylation of XPA DNA repair protein enhances its interaction with ATR protein and promotes cAMP-induced DNA repair of UV damage. J Biol Chem 293:19025-19037

Showing the most recent 10 out of 359 publications